+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Antiviral strategies in the replication of human immunodeficiency virus



Antiviral strategies in the replication of human immunodeficiency virus



L'Union Medicale du Canada 121(5): 307



The replication cycle of any virus involves a number of steps, beginning with specific attachment to a cell surface receptor leading eventually to production of progeny viruses by infected cells. In the case of the immunodeficiency virus type-1 (HIV-1), the first step involves a specific interaction between the gp120 viral envelope surface protein and specific CD4 receptor sites at the cell surface. This is followed by penetration of the virus into cells and the formation of proviral double-stranded DNA from single-stranded viral RNA, a process mediated through the action of the viral enzyme called reverse transcriptase. This, in turn, leads to the migration of proviral DNA into the nucleus of the cell and the integration of such DNA within the host cell genome. Finally both viral RNA and viral proteins are produced by the cell's genetic apparatus and new viruses are assembled at the cell surface. The fact that integration of viral DNA into host cell chromosomes occurs means that any cellular replication event will be accompanied by replication of viral DNA. Each of these steps represents a potential target for anti-viral chemotherapy. To date, most efforts to treat HIV-associated disease have focused on the reverse transcription step. In this respect, zidovudine (AZT) has been the most widely used anti-viral drug studied. However, the relative toxicity and lack of efficiency of this drug means that our efforts to develop new therapeutic strategies to combat HIV infection must continue.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039305912

Download citation: RISBibTeXText

PMID: 1279875


Related references

Novel phospholipid inhibitors of human immunodeficiency virus replication: Synthesis and antiviral activity. Bioorganicheskaya Khimiya 22(6): 451-457, 1996

Vaccine and antiviral strategies against infections caused by human immunodeficiency virus. Cmaj 138(9): 797-807, 1988

Mutagenic outcome of combined antiviral drug treatment during human immunodeficiency virus type 1 replication. Virology 307(1): 6-21, 2003

Replication of the human immunodeficiency virus strategies for inhibition. Bio/Technolgy 6(7): 794-799, 1988

Antiviral effects of plasma and milk proteins: Lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. Journal of Infectious Diseases 172(2): 380-388, 1995

High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target. Antimicrobial Agents and ChemoTherapy 49(9): 3833-3841, 2005

Heme inhibits human immunodeficiency virus 1 replication in cell cultures and enhances the antiviral effect of zidovudine. Proceedings of the National Academy of Sciences of the United States of America 88(5): 1756-1759, 1991

Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape. Journal of Virology 79(3): 1645-1654, 2005

The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents. Life Sciences 59(23): PL365-PL370, 1996

Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention. Human Gene Therapy 5(8): 927-939, 1994

Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. Journal of Virology 80(2): 875-882, 2006

Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nature Medicine 4(3): 341-345, 1998

A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. Journal of Virology 77(8): 5037-5038, 2003

The Effect of Commencing Combination Antiretroviral Therapy Soon after Human Immunodeficiency Virus Type 1 Infection on Viral Replication and Antiviral Immune Responses. The Journal of Infectious Diseases 179(3): 527-537, 1999

The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. Journal of Infectious Diseases 179(3): 527-537, 1999